Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 4 of 164 SUMMARY OF CHANGES incorporated with AMENDME NT 2 
This is a summary of changes from the Protocol dated 29 Sep 2017.   
 
 
  
 
 
  
  
  
  
  
  
   
  
 
   
  
 
  
  
   
  
 
 
   
  
   
    
 
 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 14 of 164 TABLE OF CONTENTS  
SIGNATURE PAGE  ...................................................................................................................2  
SUMMARY OF CHANGES incorporated with AMENDMENT 3  ...........................................3  
SUMMARY OF CHANGES incorporated with AMENDMENT 2  ...........................................4  
SUMMARY OF CHANGES incorporated with AMENDMENT 1  ...........................................5  
SYNOPSIS  ...................................................................................................................................6  
TABLE OF CONTENTS  ...........................................................................................................14  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ............................................19  
1 INTRODUCTION  .................................................................................................................23  
1.1 Background ........................................................................................................................23  
1.1.1  Lumbosacral Radicular Pain  ......................................................................................23  
  
1.1.3  SP-102 ........................................................................................................................25  
1.2 Preclinical Studies  ..............................................................................................................25  
1.3 Clinical Studies  ..................................................................................................................26  
 
1.5 Study Rationale  ..................................................................................................................27  
1.6 Dose Rationale  ...................................................................................................................27  
1.7 Study Endpoint Rationale ..................................................................................................28  
1.8 Risks and Benefits for Subjects .........................................................................................28  
2 STUDY OBJECTIVES  ..........................................................................................................30  
2.1 Primar y Objective  ..............................................................................................................30  
2.2 Secondary Objectives .........................................................................................................30  
3 INVESTIGATIONAL PLAN  ................................................................................................31  
3.1 Overall Study Design and Plan  ..........................................................................................31  
3.2 Study Duration  ...................................................................................................................33  
3.3 Selection of Study Population ............................................................................................33  
3.3.1  Inclusion Criteria  .......................................................................................................33  
3.3.1.1 Screening Visit Inclusion Criteria (D -22 to D-8).............................................................. 33 
3.3.1.2 Randomization Inclusion Criteria (D1) ............................................................................ 34 
3.3.1.3 Repeat Injection Inclusion Criteria (4 to 20 weeks following index injection) ................ 35  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 15 of 164 3.3.2  Exclusion Criteria  ......................................................................................................35  
3.3.3  Stopping Rules ...........................................................................................................37  
3.3.4  Removal of Subjects from Therapy or Assessment  ...................................................37  
3.4 Treatments ..........................................................................................................................37  
3.4.1  Details of Study Treatments .......................................................................................37  
3.4.2  Dosage Schedule ........................................................................................................38  
3.4.3  Treatment Assignment  ...............................................................................................39  
3.4.4  Drug Packaging and Blinding ....................................................................................39  
3.4.5  Drug Inventory and Accountability  ...........................................................................40  
3.4.6  Treatment Compliance  ...............................................................................................40  
3.4.7  Rescue Medication  .....................................................................................................40  
3.4.8  Prior and Concomitant Illnesses and Medications .....................................................40  
3.4.8.1 Prior and Concomitant Illnesses  ....................................................................................... 40 
3.4.8.2 Prior and Concomitant Medications ................................................................................. 41 
3.4.8.3 Prohibited Medications and Substances ............................................................................ 41 
3.4.9  Allowed Medications and Treatments  .......................................................................42  
3.5 Assessments .......................................................................................................................43  
3.5.1  Schedule of Assessments  ...........................................................................................43  
3.5.2  Study Procedures  .......................................................................................................48  
  
  
  
  
  
  
  
  
  
  
  
3.5.3  Repeat SP -102 Administration ..................................................................................55  
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 16 of 164   
  
3.5.4  Unscheduled Visit ......................................................................................................57  
3.5.5  Assessments for Early Termination  ...........................................................................58  
3.5.6  Efficacy Assessments .................................................................................................58  
3.5.6.1 Numeric Pain Rating Scale  ............................................................................................... 58 
3.5.6.2 Oswestry Disability Index ................................................................................................. 59 
3.5.6.3 PainDETECT .................................................................................................................... 59 
3.5.6.1 Brief Pain Inventory - Short Form .................................................................................... 59 
3.5.6.2 Clinical and Patient Global Impression Scales  ................................................................. 59 
3.5.7  Safety Assessments  ....................................................................................................60  
3.5.7.1 Physical Examination:  ...................................................................................................... 60 
3.5.7.2 General Neurological and Targeted Neurological Examinations: .................................... 60 
3.5.7.3 Vital Signs and Body Weight: .......................................................................................... 60 
3.5.7.4 Electrocardiogram:  ............................................................................................................ 60 
3.5.7.5 Laboratory Parameters:  ..................................................................................................... 61 
3.5.7.6 Adverse Events:  ................................................................................................................ 61 
3.5.7.7 Rescue Medication Use  .................................................................................................... 61 
3.5.8  Other Assessments  .....................................................................................................62  
3.5.9  Appropriateness of Measurements  .............................................................................62  
4 ADVERSE EVENT REPORTING ........................................................................................63  
4.1 Definitions and Criteria ......................................................................................................63  
4.1.1  Adverse Events  ..........................................................................................................63  
4.1.2  Serious Adverse Events .............................................................................................63  
4.1.3  Unexpected Adverse Drug Reactions  ........................................................................64  
4.1.4  Abnormal Laboratory Values ....................................................................................64  
4.1.5  Assessing Intensity and Relationship.........................................................................64  
4.2 Reporting Procedures and Requirements ...........................................................................65  
4.2.1  Adverse Events  ..........................................................................................................65  
4.2.2  Adverse Events of Special Interest  ............................................................................66  
4.2.3  Serious Adverse Events .............................................................................................66  
4.3 Procedures for Documenting Pregnancy during the Study ................................................67  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 17 of 164 5 DATA MANAGEMENT AND STATISTICAL ANALYSIS  ..............................................68  
5.1 Data Management Considerations .....................................................................................68  
5.2 Statistical Considerations  ...................................................................................................68  
5.2.1  Sample Size Justification  ...........................................................................................68  
5.2.2  Study Data  ..................................................................................................................68  
5.2.3  Defini tion of a Completed Subject ............................................................................69  
5.2.4  Analysis Methods.......................................................................................................69  
5.2.5  Analysis Populations ..................................................................................................70  
5.2.6  Protocol Deviations ....................................................................................................70  
5.2.7  Demographic and Baseline Characteristics  ...............................................................70  
5.2.8  Efficacy Analyses  ......................................................................................................70  
5.2.8.1 Primary Efficacy Endpoint ............................................................................................... 72 
5.2.8.2 Principal Analysis  ............................................................................................................. 72 
5.2.8.3 Secondary Efficacy Endpoints .......................................................................................... 72 
5.2.8.4 Secondary Efficacy Endpoint Analyses ............................................................................ 73 
5.2.8.5 Multiplicity  ....................................................................................................................... 74 
5.2.9  Safety Analyses  ..........................................................................................................74  
5.2.9.1 Adverse Events  ................................................................................................................. 74 
5.2.9.2 Electrocardiographic Data  ................................................................................................ 75 
5.2.9.3 Laboratory Data  ................................................................................................................ 75 
5.2.9.4 Vital Signs ......................................................................................................................... 75 
5.2.9.5 Neurological Examinations ............................................................................................... 75 
5.2.10  Interim Analyses  ........................................................................................................75  
6 STUDY MANAGEMENT  ....................................................................................................76  
6.1 Ethics and Consent .............................................................................................................76  
6.1.1  Regulations and Guidelines .......................................................................................76  
6.1.2  Institutional Review Board/Independent Ethics Committees  ....................................76  
6.1.3  Informed Consent.......................................................................................................76  
6.2 Discontinuation of the Study by the Sponsor ....................................................................76  
6.3 Study Documentation .........................................................................................................76  
6.4 Study Monitoring and Auditing .........................................................................................76  
6.5 Retention of Records..........................................................................................................77  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 18 of 164 6.6 Use of Study Findings ........................................................................................................77  
6.7 Publications ........................................................................................................................77  
7 REFERENCES  ......................................................................................................................78  
8 APPENDICES  .......................................................................................................................82  
Appendix A Targe ted Neurological Exam  .................................................................................82 
Appendix B Morphine Equivalents ............................................................................................83 
Appendix C BMI Table  ..............................................................................................................84 
Appendix D Instructions for Study Drug Injection ....................................................................85 Appendix E Numeric Pain Rating Scale  ....................................................................................88 
Appendix F Oswestry Disability Index ......................................................................................91 
Appendix G PainDETECT .........................................................................................................93 
Appendix H Brief Pain Inventory- Short Form  ...........................................................................95 
Appendix I  Clinician Global Impression of Severity and Clinician Global Impression of 
Change ...................................................................................................................97 
Appendix J  Patient Global Impression of Change ....................................................................98 
Appendix K Pain Catastrophizing Scale  ....................................................................................99 
Appendix L  Hospital Anxiety and Depres sion Scale  ...............................................................100 
Appendix M Daily Acetaminophen Log  ...................................................................................101 
Appendix N Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.  .....................................................................102 
Appendix O Itemized Changes made to the Protocol with Amendment 1  ...............................112 
Appendix P Itemized Changes made to the Protocol with Amendment 2. ..............................116 
Appendix Q Itemized Changes made to Protocol with Amendment 3 .....................................153 
 
TABLES  
Table 3.1:  Details of Investigational Products ....................................................................... 38  
Table 3.2:  Schedule of Assessments  ...................................................................................... 44  
 
FIGURES  
Figure  3.1:  Study Schematic .................................................................................................... 33  
Figure 3.2:  Picture of Investigational Product ......................................................................... 40  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 19 of 164 LIST OF ABBR EVIATIONS AND DEFINITIONS OF TERMS  
Abbreviation Definition  
α alpha 
µg microgram  
µmol micromole  
ADR  adverse drug reaction  
AE adverse event  
AESI  adverse event of special interest  
ALT (SGPT)  alanine aminotransferase (serum glutamic pyruvic transaminase)  
AST (SGOT)  aspartate aminotransferase (serum glutamic oxaloacetic transaminase)  
BMI  body mass index  
BPI-SF Brief Pain Inventory- Short Form  
bpm beats per minute 
C Celsius  
CDISC  Clinical Data Interchange Standards Consortium  
CD/UT  cognitive debrief and usability testing  
CFR  Code of Federal Regulations  
CGI Clinical Global Impression  
CGIC  Clinical Global Impression of Change 
CGIS  Clinical Global Impression -Severity  
Cmax maximum concentration  
CRA  clinical research associate 
CRO  contract research organization  
CSF cerebrospinal fluid  
CV coefficient of variation  
D day 
DAL  Daily Acetaminophen Log  
DB double -blind  
DDE  direct data entry  
ECG  electrocardiogram  
eCOA  electronic clinical outcome assessment  
eCRF  electronic case report form  
EOS  end of study 
ESI epidural steroid injection  
ET early termination  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 20 of 164 Abbreviation Definition  
F Fahrenheit  
FAERS  FDA Adverse Event Reporting System  
FDA  Food and Drug Administration 
FSH follicle stimulating hormone  
g gram  
GCP  Good Clinical Practice  
HADS  Hospital Anxiety and Depression Scale 
HbA1c  Hemoglobin A1c  
HIV human immunodeficiency virus 
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council on Harmonisation 
IEC independent ethics committee 
  
IND Investigational New Drug  
INR International Normalization Ratio  
IP investigational product 
IRB institutional review board  
IUD intrauterine device 
IWRS interactive web  recognition system  
LFT liver function tests  
MEDD Mean Equivalent Daily Dose 
MedDRA  Medical Dictionary for Regulatory Activities  
mITT  Modified intent- to-treat (dataset)  
mg milligram  
min minutes  
mIU milli international unit  
mL milliliter  
mm millimeter  
mmHg  millimeters of mercury  
MMRM  mixed model for repeated measures  
MRI  magnetic resonance imaging  
mRNA messenger ribonucleic acid  
NPRS  Numeric Pain Rating Scale  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 21 of 164 Abbreviation Definition  
NSAID  nonsteroidal  anti-inflammatory drug(s)  
ODI Oswestry Disability Index  
OL open- label  
PCS Pain Catastrophizing Scale 
PGIC  Patient Global Impression of Change 
po given by mouth 
PP per-protocol (dataset)  
PT prothrombin time  
PTT partial prothrombin time  
REML  restricted maximum likelihood  
RLD  Reference Listed Drug  
SAE  serious adverse event  
SAP statistical analysis plan  
SD standard deviation 
SDTM  Study Data Tabulation Model 
SOP standard operating procedure 
TEAE treatment emergent adverse event  
TF transforaminal(ly)  
Tmax time to maximum concentration  
US United States  
V visit 
W week  
WBC  white blood cells 
  
 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 22 of 164 ADMINISTRATIVE STRUCTURE  
The Study Team Contact list is provided in a separate document. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 29 of 164 of Phar maco vigilance II (DPV) identified 131 FAERS cases of neurological AEs, including 
41 cases of arachnoiditis and other serious neurological AEs ( FDA -2014 ).  Given the large 
number of ESIs , an estimated 9 million are performed annually in the US , these events are rare 
(Benzon-2015).  Even though serious neurological AEs were reported with both types of 
preparation, the case series for FAERS review contained many more reports for particulate 
steroids (n=116) compared with nonparticulate steroids (n=4), with 11 cases not reporting a formulation.  All catastrophic events (those resulting in permanent disability or death) reported to 
FAERS were associated with injection  of a suspension, whereas only a few cases involving 
temporary  symptoms were reported with glucocorticoid solutions (including dexamethasone) 
(Racoosin -2015).    
As SP-102 has been formulated as , safety issues are 
not anticipated .   
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 30 of 164 2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary objective of this study is to:  
• Evaluate the analgesic effect on average leg pain (as measured by the NPRS  in the 
affected leg ) (Appendix E ) following a single TF injection of SP-102 compared to an  
 of placebo over 4 weeks . 
2.2 Secondary Objectives  
The secondary  objectives of the study are to:  
• Evaluate degree of disability over time as measured by the Oswestry Disability Index 
(ODI)  (Appendix F ).  
• Characterize the change of the subject’s radiculopathy symptoms and overall condition using Pain DETECT  (Appendix G ), Brief Pain Inventory – Short Form (BPI -SF) 
(Appendix H ), Clinical Global Impression of Change ( CGIC ) (Appendix I ), and Patient 
Global Impr ession of Change ( PGIC ) (Appendix J ).  
• Evaluate the safety of a single and repeat  SP-102 TF injection.  
   

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 37 of 164 24. Involvement in an ongoing worker's  compensation claim, disability claim, or litigation 
related to any pain problem, receiving payments for a settled claim, awaiting pending 
payment for a settled claim , or any secondary gain in the opinion of the investigator. 
3.3.3 Stopping Rules  
A single occurrence of an adverse event of special interest ( AESI ) precludes the subject 
receiving a repeat injection.  Three occurrences of the AESI of the same type across the study will trigger stopping of all further dosing until implementation of a safety review.  
3.3.4 Removal of Subject s from Therapy or Assessment  
A subject  will be considered to have completed the study wh en he or she completes the 
W24 (D169) visit.  If a subject  is discontinued at any time after randomization into the study, the 
investigator will make every effort to follow the subject  and complete the End of Study 
(EOS)/ Early Termination  (ET)  assessments as shown in Section 3.5.1.  Sufficient subjects will 
be enrolled such that 332 subjects complete the study through W4.   
A termination electronic case report form (eCRF) page should be completed for every subject  
who receives IP, whether the subject  completes the study  or not.  The reason for any early 
discontinuation should be indicated on this form .  The primary reason for  a subject  discontinuing 
early  should be selected from the following standard categories of ET: 
• Adverse Event : Clinical or laboratory events occurred that, in the medical judgment of the 
investigator for the best interest of the subject, are grounds for discontinuation.  This 
includes serious, nonserious AEs and AESI regardless of relation to the IP. 
• Death: The subject died. 
• Withdrawal of Consent : The subject  desired to withdraw from further participation in the 
study in the absence of an investigator- deter mined medical need to withdraw.  If the 
subject  gave a reason for withdrawing, it should be recorded in the eCRF. 
• Protocol Violation: The subject ’s findings or conduct failed to meet the protocol entry 
criteria or failed to adhere to the protocol requirements (eg, drug noncompliance, failure to return for defined number of visits).  The violation necessitated early discontinued from the study. 
• Lost to Follow -Up: The subject  stopped coming for visits and study personnel were 
unable to contact the subject . 
• Other : The subject  was discontinued for a reason other than those listed above, such as 
theft, loss of IP, or termination of study by sponsor. 
3.4 Treatments  
3.4.1 Details of Study Treatments  
Information about the IPs is provided in Table 3.1 .   
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3  
  Version 4.0, 24 May 2018  
 
Confidential  Page 43 of 164  
3.5 Asse
ssments  
Unless otherwise indicated, all assessments will be performed by the investigator or designated 
study personnel and captured into eCRFs.   
3.5.1 Schedule of Assessments  
The procedures to be performed throughout the study are outlined in the Schedule of 
Assessments ( Table 3.2) .  A detailed description of each assessment may be found in 
Section  3.5.2.   

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 44 of 164 

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 45 of 164 

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 46 of 164 

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 59 of 164 subject assignment should remain the same throughout the trial, and eDiaries  should only be 
re-assigned for completed/withdrawn subjects.  The current pain intensity “pain now” will be 
measured at every clinic visit and used for assessment of accuracy of pain reporting and 
monitoring of outlier values.  Morning and afternoon pain measurements will be investigated for 
predictability of response.  
3.5.6.2 Oswestry Disability Index  
The ODI  (Appendix F ) is a validated questionnaire that was first published in 1980 but it was 
updated in 2000 ( Fairbank -1980, Fairbank -2000).  The ODI  is currently the gold standard for 
measuring degree of disability and estimating quality of life in a person with low back pain .  The 
ODI is questionnaire completed by the subject which contains 10 topics concerning intensity of 
pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to 
stand, social life, sleep quality, and ability to travel.  Each topic category is followed by 6 statements describing different potential scenarios in the subject ’s life relatin g to the topic.  
The subject  then checks the statement which most closely resembles their situation .  Each 
question is scored on a scale of 0- 5 with the first statement being zero and indicating the least 
amount of disability and the last statement is scored 5 indicating most severe disability .  The 
scores for all questions answered are summed, then multiplied by 2 to obtain the index (range 0 to 100).  Zero is equated with no disability and 100 is the maximum disability possible.  The ODI will be obtained at Screening, Baseline, W4 , W12, and W24.   
3.5.6.3 Pain DETECT 
PainDETECT  (Appendix G ) is a 7 -question validated tool to determine the prevalence of 
neuropathic pain in individuals with lower back pain.  The 7 responses are summed for a possible score ranging from 0- 35.  In addition to the 7 questions, subjects note the course of pain 
(Persistent pain with slight fluctuations; Persistent pain with pain attacks, Pain attacks without 
pain between them; Pain attacks with pain between them) for a total, overall scale score of 0 -38.  
Since its development, 4 additional questions have been added but do not contribute to scoring.  
They ask the patient to rate their pain now and over the last for weeks, and to mark on a body 
chart if their pain is radiating to other parts of the body.  Pain DETECT  will be collected at 
Screening, Baseline, W4, W12, and W24.   
3.5.6.1 Brief Pain Inventory  - Short Form  
The BPI -SF (Appendix H ) is a 15 -item self -rating scale assessing use of medications, as well as 
sensory, and reactive components of pain.  The BPI- SF includes items that will address 
components of sensory pain, including severity, location, chronicity, and degree of relief due to 
therapy.  The BPI -SF also has items that address reactive pain components, including depression, 
suffering, and perceived availability of relief.  Respectable reliability has been demonstrated over 
short intervals using test-retest correlation; worst pain, r=0.93; usual pain, r=0.78; pain now, r=0.59.  The BPI-SF will be collected at Screening, Baseline (D1), W4, W12, and W24. 
3.5.6.2 Clinical and Patient Global Impression Scales 
The CGI S (Appendix I ) is rated on an  8-point scale, with responses ranging  of responses from 
0 (not assessed ) and 1 (normal) through 7 (amongst the most severely ill subject s) (to be 
completed prior to IP administration at the Baseline (D1)  Visit).  The CGIC  (Appendix I ) scores 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 60 of 164 range from 0 (not assessed) and 1 (very much improved) through 7 (very much worse) as 
determined by the trained site rater.  The PGIC s cores range from 1  (very much improved) 
through 7 (very much worse) as assessed by the subject.  The CGIC and PGIC are obtained at 
each clinic visit following Baseline (D1) .   
3.5.7 Safety Ass essments  
3.5.7.1 Physical Examination:  
A complete physical examination, including examination of general appearance, skin, neck, eyes, ears, nose, throat, heart, lungs, abdomen, lymph nodes, extremities, and musculoskeletal  system, 
will be performed at Screening .  Specific musculoskeletal examination focusing on lumbar spine 
and lower extremities to exclude musculoskeletal sources of the predominant pain, such as SI joints and trigger points, will be performed in standardized manner and recorded.  Height (in inche s without shoes) and weight (in pounds) will be recorded at Screening.   
3.5.7.2 General Neurological and Targeted N eurological Examinations :  
A general neurological examination will include evaluation of mental status ( awareness of 
person, place, and time ), cranial nerves, motor function and balance, s ensory exam  (ability to 
feel) and reflexes .  A targeted  neurological examination  demonstrating findings of, focusing on 
signs and symptoms of lumbosacral radiculopathy, including straight leg raise test, will be performed  according to the checklist (see Appendix A ).  Both general and targeted neurological 
exams are to be performed by the same trained clinician throughout the study, if possible.  Training for conducting examination will be available on video.  General and targeted neurological examinations will be performed at Screening, Baseline (D1), W2, W4, W12, and W24, as well as if the repeat injection  is administered .  
The blinded Investigator will summarize and document the MRI findings based on the Lumbar Disc Nomenclature, the clinical presentation , and the Injection Plan in the eCRF prior to 
Baseline (D1) . 
3.5.7.3 Vital Signs and Body Weight:  
Vital signs will include systolic and diastolic BP and heart rate.  During the usual clinic visits, 
the subject is to be seated for approximately  3 min s before vital signs are recorded .  During the 
injection procedure, the vital signs will need to be collected while the subject is in prone position on the fluoroscopy table ( Appendix D ).  Vital signs will be recorded at each clinic visit.   
3.5.7.4 Electrocardiogram:  
Standard 12- lead ECGs will be measured  on the site machines at Screening .  The ECG results 
will be documented in the eCRF. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 62 of 164 3.5.8 Other Assessments  
Pain Catastrophizing Scale : PCS  (Appendix K ) is used to assess pain as a baseline 
characteristic only at Screening ( Sullivan -1995).   It was developed to quantify a subject’s pain 
experience by asking how they feel and what they think about when they are in pain.  Items on 
this scale were developed from clinical and experimental research on catastrophic thinking and its relation to experience of pain .  The PCS is a 13 -item instrument that can be completed and 
scored in less than 5 min s.  The PCS requires a reading level of approximately Grade 6.  
Hospital Anxiety and Depression Scale:  HADS  (Appendix L ) is commonly used to determine 
a subject’s anxiety and depression levels.  The scale is comprised of 14 items rated on a scale of 
0-3; 7 items focused on anxiety symptoms and 7 items focused on depression symptoms.  T he 
HADS will be used for inclusion criteria and completed at S creening only.  A score of 11-14 on 
either the depression or anxiety subscale is indicative of moderate symptomatology . A score of 
≥15 on either the depression or anxiety subscale is indicative of severe symptomatology ( Snaith -
1994, Turk -2015). Subjects with HADS scores ≥  15 will be excluded from this study  
(Zigmon d-1983 ). 
3.5.9 Appropriateness of Measurements  
All assessments to be used in this study are commonly used, standard measurements frequently 
seen in radiculopathy  studies.  
 
 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 63 of 164 4 ADVERSE EVENT REPORTING  
Throughout the course of the study, after signing the ICF, all AEs will be monitored and 
recorded on an AE eCRF, including the AE ’s description, start and end date, seriousness, 
severity, action taken, and relationship to the IP.  If AEs occur, the first concern will be the 
safety of the study subjects.  All AEs will be followed until resolved or stable and the outcome 
documented on the eCRF. 
4.1 Definitions and Criteria  
4.1.1 Adverse Events  
An AE is a ny untoward medical occurrence in a subject  or clinical investigation subject  
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment ( ICH-E2A-1996 ).  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product or not. 
Medical interventions such as surgeries, diagnostic procedures, and therapeutic procedures are 
not AEs but the action taken to treat the medical condition.  They should be recorded as treatment of the AEs.  
4.1.2 Serious Adverse Events  
A serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose:  
• Results in d eath 
• Is life -threatening  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly or birth defect  
• Is an important medical event (eg, intensive treatment in an emergency room or at home 
for allergic bronchospasm; blood dyscrasias, or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse; malignancy tumors [histologically different from primary tumor] ) 
Note: The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject  was at risk of death at the time of the event; it does not refer to an event that 
hypothetically might have caused death if it were more severe.   
Medical and scientific judg ment  should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization , but may jeopardize th e subject  or may 
require intervention to prevent one of the other outcomes listed in the definition above.  These 
should also usually be considered serious. 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 64 of 164 Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias, or convulsions that do not result in hospitalization; or 
development of drug dependency or drug abuse. 
Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  An 
SAE is not necessarily severe; eg, an overnight hospitalization for a diagnostic procedure must 
be reported as an SAE even though the occurrence is not medically serious .  By the same token, 
a severe AE is not necessarily serious: nausea of several hours’ duration may be rated as severe but may not be considered serious. 
4.1.3 Unexpected Adverse Drug Reactions  
An unexpected adverse drug reaction (ADR) is a reaction for which the nature or severity is not 
consistent with the applicable product information ( IB, SP1 02-IB-2015) .  Until product 
information is amended, expedited reporting is required for additional occurrences of the reaction .  Reports that add significant information on specificity or severity of a known, already 
documented SAE constitute unexpected events .  For example, an event more specific or more 
severe than described in the IB would be considered “ unexpected.”  Specific examples would be 
(a) acute renal failure as a labeled ADR with a subsequent new report of interstitial nephritis and 
(b) hepat itis with a first report of fulminant hepatitis.  
Guidance on reporting AEs and SAEs is described in Section  4.2. 
4.1.4 Abnormal Laboratory Values 
Any abnormality ( Appendix N ) in a laboratory value that is new in onset or which has worsened 
in severity or frequency from the baseline condition and meets 1 of the following criteria will be recorded on the AE pages of the eCRF: 
• Requires therapeutic intervention or diagnostic tests 
• Leads to discontinuation of IP 
• Has accompanying or inducing symptoms or signs 
• Is judged by the investigator as clinically significant 
4.1.5 Assessing Intensity and Relationship  
All AEs will be assessed on 2 descriptive parameters: intensity and relationship to  the IP: 
• Intensity refers to the severity of an event and references impact on a subject’s 
functioning. 
• Relationship refers to the likeliho od that the event being assessed was caused by the IP. 
Intensity  
Each AE will be classified according to Appendix N . 
When changes in the intensity of an AE occur more frequently than once a day, the maximum 
intensity for the experience should be noted.  If the intensity category changes over a number of 
days, those changes should be recorded separately (with distinct onset dates). 
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 65 of 164 Relationship  
Each AE will be assessed as to its relationship to the IP, based on the following criteria.  
Although the attribution by the investigator will be collected for reported events, for analytic 
purposes a temporal association with the use of the  IP will be assumed sufficient for at least 
plausible association. 
Investigators are required to assess the causal relationship (ie, whether there is reasonable 
possibility that the study drug caused the event) using the following definitions: 
Unrelated:  A clinical event, including laboratory te st abnormality, with a temporal 
relationship to study drug administration that makes a causal relationship 
improbable, and/or in which other drugs, chemicals or underlying disease provide plausible explanations of the event. 
Possibly Related:  A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the s tudy drug , but that could also be 
explained by concurrent disease or other drugs or chemicals .  Information 
on study drug ca usality may be lacking or unclear.  
Probably Related:  A clinical event, including laboratory test abnormality, with a reasonable 
time sequence to administration of the s tudy drug , unlikely to be attributed 
to concurrent disease or other drugs or chemicals, and that follows a clinically reasonable response on re- administration (rechallenge) or 
withdrawal (dechallenge) of the s tudy drug . 
Definitely Related:  A clinical event, including laboratory test abnormality, with a temporal relationship to study drug ad ministration that makes a causal relationship 
definite and is clearly related to use of the IP. 
When assessing the relationship to the IP, the following criteria will be considered:  
• Positive rechallenge  
• Positive dechallenge (resolution upon stopping suspec t the IP, in absence of other 
intervention or treatment) 
• Known class effect  
• Biological plausibility  
• Lack of alternative explanation —concomitant drug or disease 
4.2 Reporting Procedures and Requirements  
4.2.1 Adverse Events  
AEs occurring after the subject  signs the ICF until the 30 days after the last study visit will be 
recorded .  Any AEs occurring before the start of treatment (ie, before  the first dose of the IP)” 
will be recorded in the medical history .  Also, the sign, symptom, or disease present before 
starting the treatment period are only considered AEs if they worsen after starting the treatment 
period. 
If a subject has new or worsening pain, or onset of new neurological symptoms, a follow-up MRI 
may be obtained after consultation with the M edical Monitor.   
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 67 of 164   
  
  
Al
l recorded SAEs, regardless of relationship to study treatment, will be followed up until 
resolution, stabilization, or the subject is lost to follow -up and cannot be contacted.  In 
circumstances where the Investigator is unable to contact the subject, the Investigator must 
provide a written statement to  confirming that the subject is  lost to follow -up.  SAEs  
that are ongoing at V5 (D29)  should be followed until resolved. 
Additional follow-up information must be reported in the eCRF within 24 hours of awareness following Investigator (or site) awareness of the information.   The Investi gator should not delay 
reporting a n SAE to obtain additional information.  Additional information, when available, 
should be reported to  by the reporting procedures described 
above. 
The sponsor or its representative will be responsible for determining and in turn, reporting SAEs 
to regulatory authorities per the applicable regulatory requirements. 
4.3 Procedures for Documenting Pregnancy d uring the Study  
Pregnancy occurring in a female subject should be reported to  
within 24 hours of becoming aware of the event using the pregnancy e CRF.   The investigator 
will also: (1) notify the subject ’s physician that the subject  may have been treated with SP-102 
and (2) follow the progress of the pregnancy to term and document the outcome of the 
pregnancy.  Pregnancy outcome information should be forwarded to sponsor/  when available.  
Any pregnancies will be followed through delivery or premature termination.  If a subject 
becomes pregnant during the study, any complications of that pregnancy such as abortion 
(spontaneous or induced), premature birth, or congenital abnormality will be captured as SAEs.  
In the event the e CRF system is unavailable, a back -up paper Pregnancy Reporting Form will be 
available for  site staff to complete following reporting guidelines as outlined in Section 4.2.2. 
  

Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 75 of 164 Any TEAEs will be summarized by treatment group, for each post- randomization treatment 
period: 
• Occurring after the randomization injection, but prior to a second injection (of SP-102) 
• Occurring after the second injection (of SP-102) 
5.2.9.2 Electrocardiographic Data  
A listing of 12- lead ECG parameter  results  obtained at Screening will be presented .   
5.2.9.3 Laboratory Data 
Mean changes from Baseline (D1)  at each post -baseline time point for each laboratory variable 
will be presented .  In addition, each reading will be class ified as below, within, or above normal 
range, based on ranges supplied by the laboratory used .  Shift tables for the baseline and 
follow- up measurements will be presented.  
5.2.9.4 Vital Signs  
Summary statistics for the absolute vital sign value and the changes from baseline will be 
presented by treatment group for each visit, for each of the following vital signs:  
• Systolic blood pressure (mmHg) 
• Diastolic blood pressure (mmHg) 
• Heart rate (bpm)  
Vital sign values will be categorized  into the following potential clinical concern categories if 
applicable and summarized. 
Vital Sign  Potential Clinical Concern Categories  
Systolic blood pressure  ≥ 160 mmHg  
Diastolic blood pressure  ≥ 100 mmHg  
Heart rate  < 60 or >  100 bpm  
5.2.9.5 Neurological Examinations 
General n eurological and targeted neurological examination results will be summarized 
descriptively over time and included in listings.  
5.2.10 Interim Analyses  
No interim analysis is planned for this study.  Note that the study will be unblinded and the 
primary analysis will be completed after all subjects complete the 12- week assessments and data 
are cleaned.  Subj ects in the OL  safety extension portion of the study will continue through W24.  
No efficacy data in the first 12 weeks of the study will change after the primary analysis is 
completed.  
  
Semnur Pharmaceuticals, Inc.   Protocol SP-102-02 incorporating Amendment 3 
  Version 4.0, 24 May 2018  
Confidential  Page 76 of 164 6 STUDY MANAGEMENT  
6.1 Ethics  and Consent  
6.1.1 Regulations and Guidelines  
The study will be performed in accordance with this protocol, US  investigational new drug 
(IND) regulations (21 CFR 312), ICH guidelines  for Good Clinical Practice  (GCP), the 
regulations on electronic records and electronic signature (21 CFR 11), and the most recent 
guidelines of the Declaration of Helsinki.  
6.1.2 Institutional Review Board/Independent Ethics Committees  
Conduct of the study must be approved by an appropriately constituted institutional review board 
(IRB) .  Approval is required for the study protocol, protocol amendments, ICFs , subject  
information sheets, and advertising materials .  No IP will be shipped to a site until written IRB 
authorization has been received by the sponsor or its representative.  
6.1.3 Informed Consent  
For each trial subject , a written ICF will be obtained before any protocol- related activities .  As 
part of this procedure, the investigator or a designated representative must explain orally and in 
writing the nature, duration, and purpose of the study, and the action of the IP in such a manner 
that the subject  and (if applicable) appointed guardian are aware of the potential risks, 
inconveniences, or adverse effects that may occur .  Subject s should be informed that they may 
withdraw from the study at any time .  They will receive all information that is required by 
federal regulations and ICH guidelines.  The principal investigator or a designated representative will provide the sponsor or its representative with a copy of the IRB-approved ICF before  the 
start of the study.  
6.2 Discontinuation of the Study by the Sponsor  
The sponsor reserves the right to discontinue the study at this site or at multiple sites for safety or administrative reasons at any time .  A site that does not recruit at a reasonable rate may be 
discontinued.  Should the study be terminated, and/or the site closed for whatever reason, all 
documentation and IP pertaining to the study must be returned to the sponsor or its 
representative.  
6.3 Study Documentation  
By signing a copy of Form FDA 1572, the principal inves tigator acknowledges that he/she has 
received a copy of the IB on SP-102 and assures the sponsor that he/she will comply with the 
protocol and the provisions stated in Form FDA 1572.  No changes in this protocol can be made 
without the sponsor’s written approval. 
6.4 Study Monitoring and Auditing  
This study will be monitored for quality assurance at all stages of its development by the clinical 
research personnel employed by the sponsor or its representative.  Monitoring will include personal visits and telephone communication to assure that the investigation is conducted per  the 
protocol, standard operating procedures, Guidelines of GCP , and applicable regulatory 
requirements .  Quality control procedures will be applied to each stage of data handling to ensure 
that all data are reliable and have been processed correctly .  Remote and on- site review of eCRFs 